New Jersey A 864: Classifies xylazine as Schedule III controlled dangerous substance under certain circumstances.

Bill Text

A864 

ASSEMBLY, No. 864 

STATE OF NEW JERSEY

222nd LEGISLATURE

� 

PRE-FILED FOR INTRODUCTION IN THE 2026 SESSION

Sponsored by:

Assemblyman GERRY SCHARFENBERGER

District 13 (Monmouth)

Assemblywoman VICTORIA A. FLYNN

District 13 (Monmouth)

SYNOPSIS

���� Classifies xylazine as Schedule III controlled 
dangerous substance under certain circumstances.

CURRENT VERSION OF TEXT 

���� Introduced Pending Technical Review by Legislative 
Counsel.

�� 

An Act concerning xylazine and amending P.L.1970, c.226.

���� Be It 
Enacted by the Senate and General Assembly of 
the State of New Jersey:

���� 1.��� Section 7 of P.L.1970, 
c.226 (C.24:21-7) is amended to read as follows:

���� 7.��� Schedule III.

���� a.���� Tests. The director 
shall place a substance in Schedule III if he finds that the substance: (1) has 
a potential for abuse less than the substances listed in Schedules I and II; 
(2) has currently accepted medical use in treatment in the United States; and 
(3) abuse may lead to moderate or low physical dependence or high psychological 
dependence.

���� b.��� The controlled dangerous 
substances listed in this section are included in Schedule III, subject to any 
revision and republishing by the director pursuant to subsection d. of section 
3 of P.L.1970, c.226 (C.24:21-3), and except to the extent provided in any 
other schedule.

���� c.���� Any material, compound, 
mixture, or preparation which contains any quantity of the following substances 
associated with a stimulant effect on the central nervous system:

���� (1)�� Amphetamine, its salts, 
optical isomers, and salts of its optical isomers.

���� (2)�� Phenmetrazine and its 
salts.

���� (3)�� Any substance which 
contains any quantity of methamphetamine, including its salts, isomers, and 
salts of isomers.

���� (4)�� Methylphenidate.

���� d.��� Any material, compound, 
mixture, or preparation which contains any quantity of the following substances 
having a potential for abuse associated with a depressant effect on the central 
nervous system:

���� (1)�� Any substance which 
contains any quantity of a derivative of barbituric acid, or any salt of a 
derivative of barbituric acid, except those substances which are specifically 
listed in other schedules

���� (2)�� Chlorhexadol

���� (3)�� Glutethimide

���� (4)�� Lysergic acid

���� (5)�� Lysergic acid amide

���� (6)�� Methyprylon

���� (7)�� Phencyclidine

���� (8)�� Sulfondiethylmethane

���� (9)�� Sulfonethylmethane

���� (10) Sulfonmethane

���� (11) Ketamine hydrochloride

���� (12) Except when acquired, 
prescribed, administered, or dispensed by a veterinarian in the course of the 
professional practice of veterinary medicine, any of the following substances, 
including their salts, isomers, and salts of isomers whenever the existence of 
such salts, isomers, or salts of isomers is possible with the specific chemical 
designation:� xylazine; xylazine-M (2,6Mich dimethylaniline); xylazine-M 
(N-thiourea-2,6-dimethylaniline); xylazine-M (sulfone-HO-) isomer 2; xylazine-M 
(HO-2,6-dimethylaniline isomer 1); xylazine-M (HO-2,6-dimethylaniline isomer 
2); xylazine-M (oxo-); xylazine-M (HO-) isomer 1; xylazine-M (HO-) isomer1 
glucuronide; xylazine-M (HO-) isomer 2; xylazine-M (HO-) isomer 2 glucuronide; 
xylazine-M (HO-oxo-) isomer 1; xylazine-M (HO-oxo-) isomer 1 glucuronide; 
xylazine-M (HO-oxo-) isomer 2; xylazine-M (HO-oxo-) isomer 2 glucuronide; 
xylazine-M (sulfone); xylazine-M (sulfone-HO-) isomer 1; and any compound, 
mixture, or preparation that contains any quantity of any of the substances 
listed in this paragraph.

���� e.���� Nalorphine.

���� f.���� Any material, compound, 
mixture, or preparation containing limited quantities of any of the following 
narcotic drugs, or any salts thereof:

���� (1)�� Not more than 1.80 grams 
of codeine or any of its salts per 100 milliliters or not more than 90 
milligrams per dosage unit, with an equal or greater quantity of an 
isoquinoline alkaloid of opium.

���� (2)�� Not more than 1.80 grams 
of codeine or any of its salts per 100 milliliters or not more than 90 
milligrams per dosage unit, with one or more active, nonnarcotic ingredients in 
recognized therapeutic amounts.

���� (3)�� Not more than 300 
milligrams of dihydrocodeinone or any of its salts per 100 milliliters or not 
more than 15 milligrams per dosage unit, with a four-fold or greater quantity 
of an isoquinoline alkaloid of opium.

���� (4)�� Not more than 300 
milligrams of dihydrocodeinone or any of its salts per 100 milliliters or not 
more than 15 milligrams per dosage unit, with one or more active, nonnarcotic 
ingredients in recognized therapeutic amounts.

���� (5)�� Not more than 1.80 grams 
of dihydrocodeine or any of its salts per 100 milliliters or not more than 90 
milligrams per dosage unit, with one or more active, nonnarcotic ingredients in 
recognized therapeutic amounts.

���� (6)�� Not more than 300 
milligrams of ethylmorphine or any of it